|
Class 2 Device Recall VITROS Immunodiagnostic Products AntiSARSCoV2 IgG Quantitative Controls |
|
Date Initiated by Firm |
September 10, 2021 |
Create Date |
October 15, 2021 |
Recall Status1 |
Terminated 3 on February 13, 2024 |
Recall Number |
Z-0120-2022 |
Recall Event ID |
88737 |
Product Classification |
Reagent, coronavirus serological - Product Code QKO
|
Product |
VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Controls (IVD)- For use in monitoring the performance of the VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems when used with the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Reagent Pack used in combination with the VITROS Immunodiagnostic Products Anti- SARS-CoV-2 IgG Quantitative Calibrator for the determination of IgG antibodies to SARS-CoV-2. Product Code: 6199966 |
Code Information |
Lot Number: 0040(*and potentially future lots) UDI: 10758750034475 Exp. Date: 19NOV2021 |
Recalling Firm/ Manufacturer |
Ortho Clinical Diagnostics Inc 1001 Us Highway 202 Raritan NJ 08869-1424
|
For Additional Information Contact |
Joe Falvo 585-453-3452
|
Manufacturer Reason for Recall |
VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative Controls Outside of Expected Control Range, potential for delayed results
|
FDA Determined Cause 2 |
Under Investigation by firm |
Action |
Ortho Clinical Diagnostics issued on 10 September 2021 an "Important Product Correction Notification" letter to consignees who received VITROS Anti-SARS-CoV-2 IgG Quantitative Control, lot 0040 (Ref. CL2021-235) stating reason for notification, health risk and action to take:
While the accuracy of patient test results is not affected by this issue, there is a potential for delayed results due to the troubleshooting of Quality Control results. If standard troubleshooting does not resolve the out-of-range QC results, your facility would be unable to utilize the VITROS Anti-SARS-CoV-2 IgG Quantitative test.
Note: If QC results are within the acceptable range, your facility may continue to use VITROS Anti-SARS-CoV-2 IgG Quantitative Controls Lot 0040 with VITROS Anti-SARS-CoV-2 IgG Quantitative Reagent Lot 0030.
Resolution
VITROS Anti-SARS-CoV-2 IgG Quantitative Reagent Lots 0035 and 0040 are expected to be available mid-late September 2021.
The values currently published in the Control Value Booklet provided with VITROS Anti-SAR-CoV-2 IgG Quantitative Controls Lot 0040 are not appropriate for use with Reagent Lots 0035 and 0040.
Reagent lot specific control ranges for VITROS Anti-SARS-CoV-2 IgG Quantitative Controls Lot 0040 have been established for upcoming VITROS Anti-SARS-CoV-2 IgG Quantitative Reagent Lots 0035 and 0040 and are published on the enclosed Control Value Sheet. These revised values must be used in place of the values currently published in the Control Value Booklet provided with VITROS Anti-SARS-CoV-2 IgG Quantitative Controls Lot 0040.
An additional lot of VITROS Anti-SARS-CoV-2 IgG Quantitative Controls is also expected to be available in late September 2021.
Ortho will communicate additional lot specific control ranges as future VITROS Anti-SARS-CoV-2 IgG Quantitative Controls and Reagent lots become available.
REQUIRED ACTION
" Complete the enclosed Confirmation of Receipt form no later than September 21, 2021.
o If your facility c |
Quantity in Commerce |
US: 64 OUS: 200 |
Distribution |
Worldwide Distribution: US (Nationwide) in states of: AL, AR, AZ, CA, CO, DC, FL, ID, KS, KY, LA, ME, MI, MS, MO, NY, TN, TX and WV; and OUS (Foreign) in countries of: Australia, Brazil, Canada, Chile, China, Colombia, India, Japan, Mexico, Singapore, United Kingdom, France, Germany, Italy, Spain, Portugal, Russia, Denmark, Norway, Sweden, Belgium, and The Netherlands. |
Total Product Life Cycle |
TPLC Device Report
|
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
|
|
|